This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Teva Received FDA Approval For QVAR® (beclomethasone Dipropionate HFA) With Dose Counter

Teva Pharmaceutical Industries Ltd., (NYSE:TEVA) today announced that the U.S. Food and Drug Administration (FDA) has approved the use of QVAR ® (beclomethasone dipropionate HFA) with a dose counter for the ongoing treatment of asthma as a preventative therapy in patients five years of age and older. The dose counter is designed to help asthma patients, as well as their caregivers, keep track of the number of doses remaining in the canister. The new product will be commercially available later this year.

“Bringing QVAR ® with a dose counter to market reaffirms Teva’s commitment to addressing unmet needs by providing high-quality and innovative solutions to patients,” said Tushar Shah, MD, Senior Vice President, Teva Global Respiratory Research and Development. “Adding to our rich heritage within the respiratory space, we are pleased that all Teva Respiratory brands in the U.S. will soon include a dose counter, which will help patients and caregivers track how many doses of their medication remain.”

QVAR ® is an inhaled corticosteroid (ICS) recommended as a twice-daily treatment for long-term asthma control. Adherence to daily control medications, like QVAR ®, is important because when asthma is well controlled, fewer asthma attacks may occur.

“Inhaled corticosteroid treatments, like QVAR ®, should be taken daily by patients with mild-to-moderate persistent asthma to reduce inflammation in the airways and prevent asthma symptoms,” said Dr. Gene Colice, Director of Pulmonary, Critical Care and Respiratory Services at Washington Hospital Center in Washington, DC. “By using QVAR ® with a dose counter, patients will be able to easily track their daily doses of medication and help ensure that they are taking QVAR ® as prescribed by their doctor.”

Over the last decade, the Asthma and Allergy Network Mothers of Asthmatics (AANMA) has conducted several surveys that found patients with asthma do not have a reliable means of monitoring the contents of their metered-dose inhalers (MDIs) resulting in serious problems for many patients. Thus, AANMA recommends that all manufacturers should include dose counters as a standard feature of every metered-dose inhaler (MDI).

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $94.36 0.36%
FB $99.99 -3.90%
GOOG $674.00 -1.40%
TSLA $150.43 -7.50%
YHOO $26.70 -4.50%


Chart of I:DJI
DOW 15,892.07 -312.90 -1.93%
S&P 500 1,846.30 -33.75 -1.80%
NASDAQ 4,271.6170 -91.5270 -2.10%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs